MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
3.995
-0.165
-3.97%
Opening 15:06 09/24 EDT
OPEN
4.150
PREV CLOSE
4.160
HIGH
4.150
LOW
3.900
VOLUME
426.26K
TURNOVER
--
52 WEEK HIGH
14.87
52 WEEK LOW
3.900
MARKET CAP
320.30M
P/E (TTM)
-1.3132
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BBOT last week (0914-0918)?
Weekly Report · 3d ago
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 6d ago
Analysts’ Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX)
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Ascendis Pharma (ASND) and BridgeBio Oncology Therapeutics (BBOT)
TipRanks · 09/15 17:30
Weekly Report: what happened at BBOT last week (0907-0911)?
Weekly Report · 09/14 10:26
BridgeBio Oncology Thera Is Maintained at Overweight by JP Morgan
Dow Jones · 09/11 16:19
BridgeBio Oncology Thera Price Target Cut to $23.00/Share From $25.00 by JP Morgan
Dow Jones · 09/11 16:19
JPMorgan cuts BridgeBio target, sees buying opportunity on selloff
TipRanks · 09/11 10:55
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.